[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-31315":3,"doc-seo-31315":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},31315,1099513958762,"Logic","https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?_k=1776737595927829259",8,"Research & Report","Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) double-blind randomised placebo-controlled trial","Dulaglutide, a GLP-1 receptor agonist, was evaluated for its impact on major adverse cardiovascular events when added to standard antihyperglycaemic regimens in adults with type 2 diabetes. In a multicentre, randomised, double-blind, placebo-controlled trial across 24 countries, participants aged at least 50 years with prior cardiovascular events or risk factors were assigned to weekly dulaglutide or placebo. Over a median 5.4-year follow-up, the composite cardiovascular outcome occurred less frequently with dulaglutide, though gastrointestinal adverse events were more common.","cbCaimXtdhnmrHi8","https://ap.wps.com/l/cbCaimXtdhnmrHi8","pdf",672906,1,10,"English","en","# Summary\n## Background\n## Methods\n## Findings\n## Interpretation\n## Funding\n# Introduction","[{\"question\":\"What question did the REWIND trial assess for dulaglutide?\",\"answer\":\"Whether adding weekly dulaglutide to existing antihyperglycaemic therapy reduces major adverse cardiovascular events in people with type 2 diabetes with or without prior cardiovascular disease.\"},{\"question\":\"How was the trial designed and who participated?\",\"answer\":\"It was a multicentre, randomised, double-blind, placebo-controlled study at 371 sites in 24 countries, enrolling adults aged at least 50 years with prior cardiovascular events or cardiovascular risk factors.\"},{\"question\":\"What were the main results for the composite cardiovascular endpoint?\",\"answer\":\"During a median 5.4-year follow-up, the primary composite endpoint occurred in 12.0% with dulaglutide versus 13.4% with placebo (HR 0.88, 95% CI 0.79–0.99; p=0.026).\"},{\"question\":\"Were safety outcomes different between groups?\",\"answer\":\"All-cause mortality was broadly similar, while gastrointestinal adverse events were reported more often with dulaglutide (47.4%) than with placebo (34.1%).\"}]",1779310823,25,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":88,"head_meta":90,"extra_data":92,"updated_unix":25},105,"dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-double-blind-randomised-placebo-controlled-trial","",{"@graph":34,"@context":87},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/research-report/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-double-blind-randomised-placebo-controlled-trial/31315/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-05-20",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79,83],{"name":70,"@type":71,"acceptedAnswer":72},"What question did the REWIND trial assess for dulaglutide?","Question",{"text":73,"@type":74},"Whether adding weekly dulaglutide to existing antihyperglycaemic therapy reduces major adverse cardiovascular events in people with type 2 diabetes with or without prior cardiovascular disease.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"How was the trial designed and who participated?",{"text":78,"@type":74},"It was a multicentre, randomised, double-blind, placebo-controlled study at 371 sites in 24 countries, enrolling adults aged at least 50 years with prior cardiovascular events or cardiovascular risk factors.",{"name":80,"@type":71,"acceptedAnswer":81},"What were the main results for the composite cardiovascular endpoint?",{"text":82,"@type":74},"During a median 5.4-year follow-up, the primary composite endpoint occurred in 12.0% with dulaglutide versus 13.4% with placebo (HR 0.88, 95% CI 0.79–0.99; p=0.026).",{"name":84,"@type":71,"acceptedAnswer":85},"Were safety outcomes different between groups?",{"text":86,"@type":74},"All-cause mortality was broadly similar, while gastrointestinal adverse events were reported more often with dulaglutide (47.4%) than with placebo (34.1%).","https://schema.org",{"og:url":50,"og:type":89,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":91,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]